- Home
- AMGN vs TJX Comparison
AMGN vs TJX Comparison
Compare AMGN & TJX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- TJX
- Stock Information
- Founded
- AMGN 1980
- TJX 1962
- Country
- AMGN United States
- TJX United States
- Employees
- AMGN N/A
- TJX N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- TJX Clothing/Shoe/Accessory Stores
- Sector
- AMGN Health Care
- TJX Consumer Discretionary
- Exchange
- AMGN Nasdaq
- TJX Nasdaq
- Market Cap
- AMGN 156.2B
- TJX 134.1B
- IPO Year
- AMGN N/A
- TJX N/A
- Fundamental
- Price
- AMGN $306.95
- TJX $118.20
- Analyst Decision
- AMGN Buy
- TJX Strong Buy
- Analyst Count
- AMGN 21
- TJX 17
- Target Price
- AMGN $323.26
- TJX $135.06
- AVG Volume (30 Days)
- AMGN 3.0M
- TJX 5.3M
- Earning Date
- AMGN 05-01-2025
- TJX 05-21-2025
- Dividend Yield
- AMGN 3.10%
- TJX 1.27%
- EPS Growth
- AMGN N/A
- TJX 10.34
- EPS
- AMGN 7.56
- TJX 4.26
- Revenue
- AMGN $33,424,000,000.00
- TJX $56,360,000,000.00
- Revenue This Year
- AMGN $7.36
- TJX $5.58
- Revenue Next Year
- AMGN $2.18
- TJX $5.69
- P/E Ratio
- AMGN $40.60
- TJX $27.72
- Revenue Growth
- AMGN 18.57
- TJX 3.95
- 52 Week Low
- AMGN $253.30
- TJX $92.35
- 52 Week High
- AMGN $346.85
- TJX $128.00
- Technical
- Relative Strength Index (RSI)
- AMGN 47.38
- TJX 46.94
- Support Level
- AMGN $304.29
- TJX $119.33
- Resistance Level
- AMGN $317.58
- TJX $121.34
- Average True Range (ATR)
- AMGN 5.64
- TJX 2.11
- MACD
- AMGN -2.39
- TJX 0.55
- Stochastic Oscillator
- AMGN 13.44
- TJX 66.02
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About TJX TJX Companies Inc. (The)
TJX Companies is the leading off-price retailer of apparel, accessories, and home merchandise in the United States. The firm leverages its more than 20,000 global vendor relationships to procure and sell brand-name merchandise at prices 20%-60% cheaper than conventional retail channels. TJX opportunistically purchases excess inventory that stems from manufacturing overruns and retail closeout sales. The off-price retailer disperses its vast and disparate merchandise across its 5,000 global stores, creating a treasure-hunt shopping experience for consumers. Over three quarters of TJX's sales are derived from the United States, primarily via the T.J. Maxx, Marshalls, and HomeGoods banners. About 10% of sales are from Canada and 12% from Europe and Australia.